- Home
- PGR vs GILD Comparison
PGR vs GILD Comparison
Compare PGR & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGR
- GILD
- Stock Information
- Founded
- PGR 1937
- GILD 1987
- Country
- PGR United States
- GILD United States
- Employees
- PGR N/A
- GILD N/A
- Industry
- PGR Property-Casualty Insurers
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PGR Finance
- GILD Health Care
- Exchange
- PGR Nasdaq
- GILD Nasdaq
- Market Cap
- PGR 165.3B
- GILD 138.2B
- IPO Year
- PGR N/A
- GILD 1992
- Fundamental
- Price
- PGR $278.85
- GILD $111.79
- Analyst Decision
- PGR Buy
- GILD Buy
- Analyst Count
- PGR 16
- GILD 27
- Target Price
- PGR $280.25
- GILD $105.32
- AVG Volume (30 Days)
- PGR 3.4M
- GILD 10.3M
- Earning Date
- PGR 04-11-2025
- GILD 04-24-2025
- Dividend Yield
- PGR 1.76%
- GILD 2.83%
- EPS Growth
- PGR 118.84
- GILD N/A
- EPS
- PGR 14.40
- GILD 0.38
- Revenue
- PGR $75,343,000,000.00
- GILD $28,754,000,000.00
- Revenue This Year
- PGR $16.18
- GILD $1.77
- Revenue Next Year
- PGR $11.80
- GILD $3.52
- P/E Ratio
- PGR $19.36
- GILD $294.18
- Revenue Growth
- PGR 21.36
- GILD 6.04
- 52 Week Low
- PGR $201.34
- GILD $62.07
- 52 Week High
- PGR $292.99
- GILD $119.96
- Technical
- Relative Strength Index (RSI)
- PGR 56.19
- GILD 57.43
- Support Level
- PGR $271.00
- GILD $104.70
- Resistance Level
- PGR $277.37
- GILD $107.42
- Average True Range (ATR)
- PGR 6.38
- GILD 2.48
- MACD
- PGR -1.47
- GILD -0.62
- Stochastic Oscillator
- PGR 44.77
- GILD 57.74
About PGR Progressive Corporation (The)
Progressive underwrites private and commercial auto insurance and specialty lines; it has almost 20 million personal auto policies in force and is one of the largest auto insurers in the United States. Progressive markets its policies through independent insurance agencies in the US and Canada and directly via the internet and telephone. Its premiums are split roughly equally between the agent and the direct channel. The company also offers commercial auto policies and entered homeowners insurance through an acquisition in 2015.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).